77
Views
46
CrossRef citations to date
0
Altmetric
Research Article

Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes

&
Pages 475-484 | Published online: 08 Jul 2009

REFERENCES

  • Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Curr Opin Hematol 1996; 3: 372 — 8.
  • Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, etal. Plasminogen activator inhibitor in plasma: risk factor for recurrent myo-cardial infarction. Lancet 1987; 2: 3 — 9.
  • Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati MB, Cardillo M, et al., for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in arthero-sclerotic patients—a case-control study. Arterios-cler Thromb 1993; 13: 1412–17.
  • Held C, Hjelmdahl P, Rehnqvist N, Wallén H, Bj6rkander I, Eriksson S, et al. Fibrinolytic vari-ables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997; 95: 2380 — 6.
  • Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concen-tration on long-term mortality in patients with cor-onary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030–4.
  • Ridker PM, Vaughan PE, Stampfer MJ, Manson JE, Hennehens CH. Endogenous tissue-type plas-minogen activator and risk of myocardial infarc-tion. Lancet 1993; 341: 1165 — 8.
  • Schulman S, Wiman B. The significance of hypofi-brinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607–11.
  • Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 322: 635 — 41.
  • Thorsen S, Philips M. Isolation of tissue-type plas-minogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111 —18.
  • Booth NA, Walker E, Maughan R, Bennet B. Plas-minogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with Cl-inhibitor and PAI-1. Blood 1987; 69: 1600 —4.
  • Chandler WL, Levy WC, Stratton JR. The circula-tory regulation of TPA and UPA secretion, clear-ance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984–94.
  • Huisman LGM, van Griensven JMT, Kluft C. On the role of Cl-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466 — 71.
  • Korninger C, Collen D. Neutralisation of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for specific inhibitor. Thromb Haemost 1981; 46: 662 — 5.
  • Nilsson TK. Analysis of factors affecting tissue plasminogen activity and antigen concentration before and after venous occlusion in 123 patients. Clin Chem Enzymol Comm 1989; 1: 335–41.
  • Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991; 34: 179–92.
  • Wiman B. Affinity-chromatographic purification of human a-antiplasmin. Biochem J 1981; 191: 229 — 32.
  • Nilsson T, Wiman B. Purification and characteriza-tion of human Cl -esterase inhibitor. Biochim Biophys Acta 1982; 705: 271 — 6.
  • Lindahl T, Wiman B. Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium. Biochim Biophys Acta 1989; 994: 253–7.
  • Lindahl T, Sigurdardottir 0, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748 — 51.
  • Tijssen P, Kurstak E. Highly efficient and simple methods for preparation of peroxidase and active peroxidase-antibody conjugates for enzyme immu-noassays. Analyt Biochem 1984; 136: 451 —7.
  • Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Evidence for sec-ond-site interactions. Biochem J 1988; 251: 327 — 33.
  • Laemmli UK. Cleavage of structural proteins dur-ing the assembly of the head bacteriophage T4. Nature 1970; 227: 680 — 5.
  • Urdén G, Hamsten A, Wiman B. Comparison of plasminogen activator inhibitor activity and anti-gen in plasma samples. Clin Chim Acta 1987; 169: 189— 96.
  • Ranby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost 1989; 61: 409 — 14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.